Big pharma, Financing, Top 50 Pharma

Watson prices debt financing offering of $1.2 billion

Posted on 02 October 2012

Tags: , ,

Watson Pharmaceuticals announced the pricing of a debt financing offering of $1.2 billion of 1.875% senior notes due 2017, $1.7 billion of 3.250% senior notes due 2022 and $1.0 billion of 4.625% senior notes due 2042, for a total offering of $3.9 billion in aggregate principal amount.

Watson intends to use the net proceeds from this financing offering to fund a portion of the cash consideration for Watson's previously announced acquisition of the privately-held Actavis Group.

For further deal information visit Current Agreements (subscription required)



Read: more on financing deals in pharma, biotech, life science partnering deal news, insights and glossary

Read: Big pharma deal news - latest deal news for top 50 pharma / big pharma companies

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value

View: Current Partnering’s Financing Scorecard – view top life science financing deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Print Friendly, PDF & Email

Leave a Reply